- Home
- ICU vs CVKD Comparison
ICU vs CVKD Comparison
Compare ICU & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- CVKD
- Stock Information
- Founded
- ICU 2018
- CVKD 2022
- Country
- ICU United States
- CVKD United States
- Employees
- ICU N/A
- CVKD N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- ICU Health Care
- CVKD Health Care
- Exchange
- ICU Nasdaq
- CVKD Nasdaq
- Market Cap
- ICU 25.6M
- CVKD 29.5M
- IPO Year
- ICU N/A
- CVKD 2023
- Fundamental
- Price
- ICU $0.86
- CVKD $12.64
- Analyst Decision
- ICU
- CVKD Strong Buy
- Analyst Count
- ICU 0
- CVKD 1
- Target Price
- ICU N/A
- CVKD $32.00
- AVG Volume (30 Days)
- ICU 1.1M
- CVKD 24.4K
- Earning Date
- ICU 11-12-2025
- CVKD 11-06-2025
- Dividend Yield
- ICU N/A
- CVKD N/A
- EPS Growth
- ICU N/A
- CVKD N/A
- EPS
- ICU N/A
- CVKD N/A
- Revenue
- ICU $766,000.00
- CVKD N/A
- Revenue This Year
- ICU $894.81
- CVKD N/A
- Revenue Next Year
- ICU $71.78
- CVKD N/A
- P/E Ratio
- ICU N/A
- CVKD N/A
- Revenue Growth
- ICU N/A
- CVKD N/A
- 52 Week Low
- ICU $0.31
- CVKD $8.74
- 52 Week High
- ICU $5.22
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- ICU 53.00
- CVKD 48.59
- Support Level
- ICU $0.82
- CVKD $13.12
- Resistance Level
- ICU $0.91
- CVKD $13.69
- Average True Range (ATR)
- ICU 0.07
- CVKD 0.59
- MACD
- ICU -0.00
- CVKD -0.06
- Stochastic Oscillator
- ICU 48.31
- CVKD 21.08
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.